Patents by Inventor Richard L. Beard

Richard L. Beard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5,6,7,8-Tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
    Publication number: 20040198825
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: April 3, 2003
    Publication date: October 7, 2004
    Inventors: Richard L. Beard, Haiqing Yuan, Roshantha A. Chandratratna
  • Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
    Publication number: 20040147611
    Abstract: Diabetic mammals are treated with compounds that are significantly more efficacious as agonists of RXR&bgr; retinoid receptors than as agonists of RXR&agr; or RXR&ggr; retinoid receptors. The treatment reduces serum glucose and triglyceride levels of the mammals without the undesirable side effects of reducing serum thyroxine levels and a transient increase in serum triglyceride levels Compounds suitable for use in the methods of treatments of the present invention are selected by testing and identifying compounds of selective or specific efficacy as agonists of RXR&bgr; retinoid receptors in preference over RXR&agr; and/or RXR&ggr; retinoid receptors. Novel compounds used in the methods of the invention have Formula 1 where the variables are defined as disclosed in the specification.
    Type: Application
    Filed: December 17, 2003
    Publication date: July 29, 2004
    Inventors: Yang-Dar Yuan, Richard L. Beard, Roshantha A. Chandraratna
  • 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6759547
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: July 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Haiqing Yuan, Yang-Dar Yuan, Roshantha A. Chandraratna
  • 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6759546
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: July 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Richard L. Beard, Haiqing Yuan, Roshantha A. Chandratratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Publication number: 20040127469
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: December 9, 2003
    Publication date: July 1, 2004
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
    Publication number: 20040097733
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: July 2, 2003
    Publication date: May 20, 2004
    Inventors: Richard L. Beard, Thong Vu, Diana F. Colon, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6734193
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: May 11, 2004
    Assignee: Allergan, Inc.
    Inventors: Tien Duong, Richard L. Beard, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6720425
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: April 13, 2004
    Assignee: Allergan, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6653483
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: November 25, 2003
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Publication number: 20030187235
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: December 9, 2002
    Publication date: October 2, 2003
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
    Publication number: 20030166932
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: January 4, 2002
    Publication date: September 4, 2003
    Inventors: Richard L. Beard, Thong Vu, Diana F. Colon, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
    Patent number: 6613917
    Abstract: Compounds of the formula where the symbols are as defined in the specification, have retinoid agonist, antagonist or negative hormone-like biological activity.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: September 2, 2003
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Thong Vu, Diana F. Colon, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • Composition and method for modulating BAR/FXR receptor activity
    Publication number: 20030144360
    Abstract: Methods for modulating the activity of the mammalian BAR/FXR receptor. The methods include methods of treating a hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds able to modulate an activity characteristic of the BAR/FXR receptor. Other methods include a method of treating colon cancer in a mammal comprising administering a compound having a BAR/FXR antagonistic activity.
    Type: Application
    Filed: March 22, 2002
    Publication date: July 31, 2003
    Applicant: Allergan Sales, Inc.
    Inventors: Barry M. Forman, Richard L. Beard, Isabelle Dussault, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6555690
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: April 29, 2003
    Assignee: Allergan, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Publication number: 20030078440
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: October 11, 2002
    Publication date: April 24, 2003
    Inventors: Vidyasagar Vuligonda, Min Teng, Richard L. Beard, Alan T. Johnson, Yuan Lin, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Patent number: 6521624
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: February 18, 2003
    Assignee: Allergan, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Publication number: 20020173631
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: May 8, 2002
    Publication date: November 21, 2002
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
    Publication number: 20020156054
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Application
    Filed: March 28, 2001
    Publication date: October 24, 2002
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Synthesis and use of retinoid compounds having negative hormone and/or anatgonist activities
    Patent number: 6469028
    Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: October 22, 2002
    Assignee: Allergan, Inc.
    Inventors: Elliott S. Klein, Alan T. Johnson, Andrew M. Standeven, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Sunil Nagpal, Vidyasagar Vuligonda, Min Teng, Roshantha A. Chandraratna
  • Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity
    Patent number: 6465647
    Abstract: Compounds of the Formula 1, Formula 2, Formula 3 and Formula 4 wherein the symbols have the meaning assigned to them in the disclosure have retinoid-like biological activity.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: October 15, 2002
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Diana F. Colon, Roshantha A. Chandraratna